Tarsus Pharmaceuticals (TARS) announced that the first participant has been dosed in the Phase 2 clinical trial evaluating TP-05, a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
- Tarsus Pharmaceuticals to receive $15M milestone on China TP-03 approval
- Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
- Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer
- Tarsus Pharmaceuticals price target raised to $90 from $87 at Guggenheim